IP Library Patent Application 11000553
Patent Application
App. No. 11/000,553

Methods and devices for maintaining patency of surgically created channels in a body organ

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/000,553
Abstract

This is directed to methods and devices suited for maintaining an opening in a wall of a body organ for an extended period. More particularly devices and methods are directed maintaining patency of channels that alter gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having chronic obstructive pulmonary disease.

Claims (22)

1 . An implant to maintain an opening in the airway wall of a lung comprising: a support member;

a non-bioabsorbable polymer comprising a plurality of diffusion paths having at least one additive, where the additive is water soluble; and

an antiproliferative agent, where on implantation of the implant into the airway wall and upon dissolving of the additive, the plurality of diffusion paths allow for improved passage of the antiproliferative agent into the airway wall.

2 . The implant of claim 1 where the antiproliferative agent comprises an amount that does not exhibit substantial cytotoxicity but controls the healing response by suppressing hyperplasia of lung tissue, to maintain patency of an artificial opening in the airway which allows for maintaining air passage between the opening and parenchyma for a sufficient time until the healing response of the lung tissue subsides such that the opening essentially becomes a natural airway passage.

3 . The implant of claim 1 , where the polymer is selected from a group consisting of thermoplastic polymers, thermoset polymers, acrylate polymers, a blend of acrylate-methacrylate polymers, silicone elastomers, urethane elastomers, ethylene vinyl acetate polymers, polyethylene, polypropylene, PLA-PGA, PLA, PGA, polyortho-ester, polycapralactone, polyester, hydrogels, polystyrene, co-polymers of styrene-isobutylene-styrene, and combinations or blends thereof.

4 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule stabilizing agent.

5 . The implant of claim 4 , where the microtubule stabilizing agent is paclitaxel, taxotere, epothilone-B.

6 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule destabilizing agent.

7 . The implant of claim 6 , where the microtubule destabilizing agent is selected from the group comprising vincristine, vinblastine, podophylotoxin, estramustine, noscapine, griseofulvin, dicoumarol, a vinca alkaloid, or a combination thereof.

8 . The implant of claim 1 , where the antiproliferative substance comprises a substance selected from the group consisting of steroids, non-steroidal anti-inflammatories, and d-actinomycin, and a combination thereof.

9 . The implant of claim 1 , where the antiproliferative substance comprises a cytostatic agent.

10 . The implant of claim 9 , where the cytostatic agent is selected from the group consisting of: sirolimus, everolimus, ABT-578, biolimus, tacrolimus, and a combination thereof.

11 . The implant of claim 1 , where the additive is selected from a group categorized as ionic, non-ionic, or polymeric.

12 . The implant of claim 1 , where the support member is non-expandable.

13 . The implant of claim 1 , where the support member is expandable.

14 . The implant of claim 1 , where the support member is tubular in shape.

15 . The implant of claim 1 , where the support member is a grommet.

16 . An implant to maintain an opening in the airway wall of a lung comprising:

a support member; and

a multi-polymer comprising a plurality of drugs.

17 . The implant of claim 16 where at least one of the drugs are antiproliferative agents having an amount that does not exhibit substantial cytotoxicity but controls the healing response by suppressing hyperplasia of lung tissue, to maintain patency of an artificial opening in the airway which allows for maintaining air passage between the opening and parenchyma for a sufficient time until the healing response of the lung tissue subsides such that the opening essentially becomes a natural airway passage.

18 . The implant of claim 17 , where at least one drug is a microtubule stabilizing agent and at least one is a microtubule destabilizing agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2005
From: PHAN, LOC; ROSCHAK, ED
To: BRONCUS TECHNOLOGIES, INC.
Reel/Frame 016566/0345 →